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Abstract
Background: Randomized trials show that male circumcision (MC) reduces the incidence of HIV and herpes simplex virus
type 2 (HSV-2) infections, and symptomatic genital ulcer disease (GUD). We assessed the role of GUD and HSV-2 in the
protection against HIV afforded by MC.
Methods and Findings: HIV-uninfected men were randomized to immediate (n=2,756) or delayed MC (n=2,775) in two
randomized trials in Rakai, Uganda. GUD symptoms, HSV-2 status, and HIV acquisition were determined at enrollment and at
6, 12, and 24 mo of follow up. Ulcer etiology was assessed by PCR. We estimated the prevalence and prevalence risk ratios
(PRRs) of GUD in circumcised versus uncircumcised men and assessed the effects of HSV-2 serostatus as a risk-modifying
factor for GUD. We estimated the proportion of the effect of MC on HIV acquisition that was mediated by symptomatic
GUD, and by HSV-2 infection. Circumcision significantly reduced symptomatic GUD in HSV-2-seronegative men (PRR=0.51,
95% [confidence interval] CI 0.43–0.74), HSV-2-seropositive men (PRR=0.66, 95% CI 0.51–0.69), and in HSV-2 seroconverters
(PRR=0.48, 95% CI 0.30–0.79). The proportion of acute ulcers due to HSV-2 detected by PCR was 48.0% in circumcised men
and 39.3% in uncircumcised men (x
2 p=0.62). Circumcision reduced the risk of HIV acquisition in HSV-2 seronegative men
(incidence rate ratio [IRR]=0.34, 95% CI 0.15–0.81), and potentially in HSV-2 seroconverters (IRR=0.56, 95% CI 0.19–1.57; not
significant), but not in men with prevalent HSV-2 at enrollment (IRR=0.89, 95% CI 0.49–1.60). The proportion of reduced HIV
acquisition in circumcised men mediated by reductions in symptomatic GUD was 11.2% (95% CI 5.0–38.0), and the
proportion mediated by reduced HSV-2 incidence was 8.6% (95% CI 21.2 to 77.1).
Conclusions: Circumcision reduced GUD irrespective of HSV-2 status, but this reduction played only a modest role in the
protective effect of circumcision on HIV acquisition.
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Three randomized trials in South Africa [1], Kenya [2], and
Uganda [3] found that male circumcision (MC) reduces the risk of
HIV acquisition in men, a finding supported by prior observa-
tional studies [4]. The foreskin is rich in HIV target cells and the
inner preputial mucosa is thought to be lightly keratinized and
vulnerable to HIV infection [5–8]. Thus, it is hypothesized that
circumcision may reduce HIV infection by removal of this
vulnerable tissue. The Ugandan trial also found that circumcision
decreased the rate of self-reported genital ulcer disease (GUD) [3]
and the incidence of herpes simplex virus type 2 (HSV-2) [9]; these
findings had previously been suggested by observational studies
[10]. The South African trial reported that circumcision was
equally protective against HIV acquisition in HSV-2 seropositive
and seronegative men [11]. GUD, particularly due to HSV-2, is
thought to be a cofactor for HIV acquisition [12–14]. Thus it is
possible that circumcision prevents HIV in part by reducing
genital ulceration and HSV-2.
We conducted a secondary data analysis from the randomized
trials of MC for HIV prevention in Rakai, Uganda, to assess the
degree to which circumcision-related reductions in symptomatic
genital ulcers and HSV-2 potentially mediated the effect of MC on
HIV prevention.
Methods
We conducted two concurrent randomized trials that enrolled
consenting uncircumcised men aged 15–49 y and randomized
them to receive immediate circumcision (intervention arm), or
circumcision delayed for 24 mo (control arm) (Text S3). Details
have been published previously [3,9]. Participants provided
written informed consent for screening, enrollment, and follow
up, and men receiving circumcision also provided written consent
for surgery. Participants were followed at 6, 12, and 24 mo and
interviewed with regard to sexual risk behaviors and self-reported
genital ulceration during the preceding follow-up interval, as well
as recent GUD symptoms within 1 wk of the study visit. In
addition, a genital exam was performed and swabs taken from any
observed penile lesion. One trial supported by the National
Institutes of Health (NIH) enrolled HIV-negative men who, as
condition for enrollment eligibility, accepted voluntary counseling
and testing (VCT) and agreed to learn their HIV results. A second
trial, supported by the Bill & Melinda Gates Foundation, enrolled
HIV-negative men who accepted pre-test counseling but declined
to learn their HIV results, and thus were ineligible for enrollment
in the NIH trial. Under Ugandan policy persons may provide
blood for testing but decline to learn their test result, and such
individuals were not denied access to trial participation. All
participants were offered intensive HIV prevention education,
access to free HIV VCT, and condoms, provided free of charge,
and were strongly encouraged at each study visit to practice safe
sex behaviors and to avail themselves of VCT and condoms. The
trials are registered with ClinicalTrials.gov numbers
NCT00425984 for NIH trial and NCT00124878 for the Gates
Foundation trial. The protocol (see Text S1 and Text S2) was
reviewed and approved by the Uganda National Council for
Science and Technology, and by three Institutional Review
Boards (IRBs): the Science and Ethics Committee of the Uganda
Virus Research Institute, Entebbe, Uganda; the Committee for
Human Research at Johns Hopkins University, Bloomberg School
of Public Health; and the Western Institutional Review Board,
Olympia, Washington. The data were analyzed without personal
identifiers.
The objective of this analysis was to assess the degree to which
GUD and HSV-2 serostatus contributed to the reduced HIV
incidence observed in circumcised men. This analysis used data
from all initially HIV-uninfected men enrolled in either trial who
contributed follow-up time for determination of incident HIV
infection, and for whom we had HSV-2 serology at enrollment
and follow up. The trial profile is given in Figure 1. 6,396 men
were screened of whom 5,534 HIV-negative men were enrolled.
There were a total of 2,756 HIV-negative men enrolled in the
intervention arm of either trial and 2,775 men enrolled in the
control arm of either trial available for this analysis. Of these
enrolled participants, 2,319 intervention arm (84.1%) and 2,339
control arm (84.3%) were followed over 2 y.
The enrollment blood samples for these men were tested for
HSV-2 antibodies using the HSV-2 ELISA (Kalon Biological
Ltd.). On the basis of prior evaluation of test performance in
Ugandan sera using HSV-2 University of Washington Western
blot as the gold standard, HSV-2 positive status was defined as a
Kalon ELISA index value of $1.5 [15]. Men with a Kalon index
value #0.9 were classified as HSV-2 negative. Trial enrollment
samples with Kalon index values between 0.90–1.49 were
classified as indeterminate HSV-2 status. Only HSV-2 negative
individuals were evaluated for HSV-2 seroconversion (index value
$1.5). All seroconversions were confirmed by Euroimmun
Western blot (Euroimmun). HSV-2 serostatus was classified into
four mutually exclusive groups; HSV-2 positive at enrollment,
HSV-2 indeterminate at enrollment, HSV-2 seronegative at
enrollment and throughout follow up, and HSV-2 seroconver-
sions. HIV status was determined by two separate ELISAs and
confirmed by HIV-1 Western blot, as previously described [3].
Serologic syphilis was assessed at each study visit on the basis of a
positive rapid plasma reagin (RPR) (Becton Dickinson) or toluidine
red unheated serum test (TRUST) (New Horizons Diagnostics
Corporation) and confirmed by a positive Treponema pallidum
particle agglutination assay (TPPA) (Serodia-TP PA kit, Fujirebio
Inc.).
For men who had a genital lesion observed at the time of a study
visit, a swab was obtained for detection of Haemophilus ducreyi, T.
pallidum, HSV-1, and HSV-2 using real-time multiplex PCR [16–
18]. Two multiplex real-time PCR reactions using fluorescent
probes for two pathogens in a single reaction (H. ducreyi and T.
pallidum or HSV-1 and HSV-2), were performed on extracted
DNA. Samples were run in duplicate, and discordant results were
repeated in a single-pathogen real-time PCR reaction.
Statistical Analysis
Enrollment sociodemographic and behavioral characteristics of
intervention and control arm participants, and the characteristics
of HSV-2 seropositive and seronegative men were compared.
Differences between groups were assessed using Chi-square tests.
At each study visit, we assessed the frequency of self-reported
GUD during the preceding follow-up interval to estimate the
period prevalence of GUD per 100 follow-up visits. Prevalence risk
ratios (PRRs) and 95% confidence intervals (95% CI) estimated by
modified Poisson regression [16] were used to assess differences in
GUD frequency between study arms and strata of HSV-2 status.
Because men could report multiple episodes of symptomatic
ulceration in different follow-up intervals, robust variance
estimates based on generalized estimating equations were used
to account for within-individual correlation. We also assessed the
point prevalence of GUD observed at the time of a study visit and
the proportion of ulcer swabs with sexually transmitted infection
(STI) pathogens detected by real-time PCR.
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interval and cumulated interval-specific incident HIV events
a n dp e r s o nt i m eo v e rt h ep e r i o do fo b s e r v a t i o n .T h e r ew e r ea
total of 105 incident HIV infections, 36 in the intervention arm
and 69 in the control arm participants. HIV incidence rates were
estimated per 100 person years (py) assuming that infection
occurred midway between the lastH I V - n e g a t i v ea n df i r s tH I V -
positive serologic test. Differences in HIV incidence between
study arms, stratified by HSV-2 status and GUD symptoms were
assessed by incidence rate ratios (IRRs) and 95% CI estimated by
Poisson multiple regression after adjustment for covariates found
to be significantly associated with HIV acquisition in univariate
analyses at p,0.15. The covariates used in adjusted models
included age, maritalstatus, number of sex partners, and condom
use. Exact 95% CI were estimated if any cell contained less than
five observations.
We hypothesized that GUD and incident HSV-2 could be
intermediate factors between circumcision and HIV acquisition,
because both are reduced by circumcision and are related to incident
HIV.Therefore,weconducted amediationanalysisusingtwologistic
regression models, one estimating the net effect of circumcision on
HIV incidence without adjustment for the intermediate variables,
and the second model estimating the direct effects of circumcision on
HIV acquisition after adjustment for potential mediating variables
(GUD or incident HSV-2) [19]. We then estimated the proportion of
the circumcision effect on HIV acquisition explained by the effects of
circumcision on intermediate variables using the expression
p~ 1{
^ b badj
^ b b
 !
,w h e r e^ b badj is the coefficient estimate of the
circumcision effect from the model including the intermediate
variable, and ^ b b is the coefficient from the model without the
intermediate variable. The confidence interval for p was obtained
using bias corrected and accelerated (BCa) bootstrap confidence
intervals. Specifically, since the incidence of HIV was rare, we used a
stratified bootstrap method by bootstrapping in the HIV incidence
samples and nonincidence samples, respectively. All the analyses were
performed in R 2.8.1 environment. The whole trial population was
assessed for the mediating effect of GUD, since circumcision was
found to reduce GUD, irrespective of HSV-2 serostatus.To assess the
mediating effect on incident HSV-2 infection, the population was
restrictedtomenwhowereHSV-2negativeatenrollmentandthusat
risk of HSV-2 seroconversion during follow up.
We also estimated the attributable risk (AR) of incident
HIV associated with GUD or HSV-2 using the formula
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1000187.g001
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P(HIV)
[20], where exposure is
GUD or HSV-2 seroconversion, respectively. The standard
errors of the AR were estimated from log (1{AR) for 95% CI
calculations. ARs of HIV acquisition associated with GUD or
HSV-2 were estimated separately by study arm. To test the
null hypothesis that the AR associated with GUD or HSV-2 is
the same between study arms, the p-value for the difference in
AR between arms was calculated by comparing the approx-
imated normal distributions of log (1{AR) for the two arms.
Results
Table 1 shows the distribution of participant characteristics at
enrollment. HSV-2 prevalence was 28.3% (782/2,576) in the
intervention arm and 27.4% (759/2,775) in the control arm.
HSV-2 indeterminate serostatus (Kalon Elisa index values 1.0 to
1.49) was similar in intervention (10.1%, 278/2,756) and control
arms (10.8%, 299/2,775), and 61.5% of intervention arm men
(1696/2,756) versus 61.7% of control arm men (1,717/2,775)
were HSV-seronegative at enrollment. The two study arms were
also comparable with respect to sociodemographic and behav-
ioral characteristics (Table 1). However, there were marked
differences in the characteristics of men who were HSV-2
seropositive and seronegative at enrollment. Compared to HSV-
2 negative men, HSV-2-positive men were significantly older
(40+ y, 13.9% versus 2.6%, x
2 p,0.0001), more likely to be
currently or previously married (77.2% versus 42.5%, x
2
p,0.0001), to have a higher number of reported sex partners
in the past year (2+ 43.8% versus 31.8%, x
2 p,0.0001), and were
less likely to consistently use condoms (7.9% versus 16.9%, x
2
p,0.0001).
As shown in Table 2, the period prevalence of self-reported
GUD per 100 study visits was significantly lower in the
intervention than the control arm men (PRR 0.59, 95% CI
0.50–0.69, Wald test, p,0.0001). In a multivariate model,
adjusted for age, number of sexual partners, and condom use,
the PRR of GUD associated with circumcision was 0.54 (95% CI
0.44–0.66). Other covariates significantly associated with lower
symptomatic GUD were having no sex partners during the follow-
up interval (PRR=0.26, 95% CI 0.16–0.42) and consistent
condom use (PRR=0.63, 95% CI 0.43–0.92). The prevalence
of self-reported GUD was significantly lower in the intervention
than the control arm irrespective of HSV-2 status at enrollment or
HSV-2 acquisition during follow up, although the highest rates of
symptomatic GUD were reported among men who seroconverted
to HSV-2 during the trial.
The point prevalence of clinically observed GUD reported at
the time of a study visit was 0.8% in the intervention arm (53/
6,554 visits) and 1.9% (121/6,544 visits) in the control arm
(PRR=0.44, 95% CI 0.32–0.61). Swabs for multiplex PCR were
obtained from visible lesions in 25 symptomatic intervention arm
men and 56 symptomatic control arm men. HSV-2 was detected
in 48.0% (12/25) of GUD swabs assayed among symptomatic
circumcised men, and 39.4% (22/56) of swabs assayed for
symptomatic uncircumcised men (x
2 p=0.62). No T. pallidum
was detected by PCR in intervention arm men, whereas seven T.
pallidum infections were found among control arm participants
(9.6%, x
2 p=0.09). No cases of ulcers due to H. ducreyi or HSV-1
were detected in either study arm. It is noteworthy that of those
symptomatic participants tested by PCR, no STI pathogen was
detected in 52.0% of 25 intervention arm men and 60.7% of 56
control arm men, suggesting that many observed lesions did not
have an STI etiology.
Table 1. Characteristics of the study populations at enrollment.
Enrollment HSV-2 Positive Enrollment HSV-2 Negative All Participants
Intervention Control Intervention Control Intervention Control
Characteristics and
Behaviors n Percent n Percent n Percent n Percent n Percent n Percent
All 782 100.0 759 100.0 1,696 100.0 1,717 100.0 2,756 100.0 2,775 100.0
Age (y)
15–29 412 52.7 389 51.2 1,379 81.3 1,430 83.2 1,988 72.1 2,037 73.4
30–39 267 34.1 261 34.3 269 15.9 247 14.4 598 21.7 575 20.7
40+ 103 13.2 110 14.5 48 2.8 41 2.4 170 6.2 163 5.9
Marital status
Currently married 534 68.3 519 68.4 658 38.8 654 38.1 1,340 48.6 1,332 48.0
Previously married 65 8.3 71 9.4 82 4.8 56 3.3 165 6.0 141 5.1
Never married 183 23.4 169 22.3 956 56.4 1,007 58.7 1,251 45.4 1,302 46.9
Sex partners in past year
None 74 9.5 63 8.3 363 21.4 402 23.4 493 17.9 518 18.7
One 368 47.1 362 47.7 786 46.3 776 45.2 1,288 46.7 1,279 46.1
Two 219 28.0 237 31.2 348 20.5 367 21.4 621 22.5 670 24.1
Three or more 121 15.5 97 12.8 199 11.7 172 10.0 354 12.8 308 11.1
Condom use
None 469 60.0 436 57.4 942 55.5 957 55.7 1,589 57.7 1,564 57.7
Inconsistent 254 32.5 261 34.4 466 27.5 474 27.6 791 28.7 826 29.8
Consistent 59 7.5 62 8.2 288 17.0 286 16.7 376 13.6 385 13.9
doi:10.1371/journal.pmed.1000187.t001
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men with positive syphilis serology during follow-up visits. Among
these individuals, GUD symptoms were reported during the
follow-up interval preceding serologic syphilis detection in 4.5% of
visits by intervention arm men (9/202), and in 13.3% of visits in by
control arm men (26/195, PRR=0.33, 95% CI 0.16–0.69, x
2
p=0.003). Among men who were T. pallidum seronegative
throughout the study, the frequency of GUD symptoms was
3.2% (226/7,942 visits) in intervention arm men and 5.8% (413/
7,095 visits) in control arm men (PRR=0.55, 95% CI 0.47–0.65).
HIV incidence is shown in Table 3. HIV incidence was 0.78/
100 py among circumcised men and 1.44/100 py among
uncircumcised men (IRR=0.54, 95% CI 0.35–0.78). HIV
incidence was lower in circumcised than in uncircumcised men
with self-reported symptomatic GUD (IRR=0.55, 95% CI 0.20–
1.50), although this difference was not statistically significant.
However, circumcision was significantly protective against HIV
acquisition in men without GUD symptoms (IRR=0.57, 95% CI
0.37–0.89). We did not observe a reduction in the risk of HIV
acquisition among men who were HSV-2 positive at enrollment
(IRR=0.89, 95% CI 0.49–1.60), irrespective of whether the
prevalent HSV-2 positive men reported GUD symptoms
(IRR=0.92, 95% CI 0.15–4.90) or were asymptomatic
(IRR=0.94, 95% CI 0.49–1.81). The interaction between HSV-
2 seropositive status and treatment arm was not statistically
significant (likelihood ratio p=0.07).
Because these findings were contrary to those reported in the
South African trial, which observed circumcision efficacy against
HIV acquisition irrespective of HSV-2 serostatus [11], we
conducted a sensitivity analysis confined to the age group enrolled
Table 2. Self reported genital ulceration by enrollment HSV-2 status and study arm.
Intervention Control
HSV-2 Status at Enrollment GUD/n Visits GUD Percent GUD/n Visits GUD Percent PRR Intervention/Control (95% CI)
All 212/7,332 2.9 361/7,353 4.9 0.59 (0.50–0.69)
HSV-2 Status
HSV-2 positive 91/2,111 4.3 134/2,056 6.5 0.66 (0.51–0.84)
HSV-2 indeterminate 29/753 3.9 48/785 6.1 0.63 (0.41–0.96)
HSV-2 seroconverters 18/336 5.4 50/452 11.1 0.48 (0.30–0.79)
Persistent HSV-2 negative 74/4,132 1.8 129/4,060 3.2 0.51 (0.43–0.74)
doi:10.1371/journal.pmed.1000187.t002
Table 3. HIV incidence by self-reported GUD and HSV-2 status and study arm.
Intervention Control
HSV-2 Status at Enrollment HIV Cases/py HIV Incidence/100 py HIV Cases/py HIV Incidence/100 py IRR Intervention/Control (95% CI)
All 36/4,825.5 0.78 69/4,846.0 1.44 0.54 (0.35–0.78)
GUD symptoms 5/173 2.89 16/303.5 5.27 0.55 (0.20–1.50)
No GUD 31/4,652.5 0.70 53/4,542.5 1.18 0.57 (0.37–0.89)
HSV-2 positive
All 21/1,392 1.51 23/1,358.5 1.69 0.89 (0.49–1.60)
GUD symptoms 3/74 4.1 5/117.5 4.26 0.92 (0.15–4.90)
No GUD 18/1,318 1.37 18/1,241 1.45 0.94 (0.49–1.81)
HSV-2 indeterminate
All 3/501 0.60 14/519 2.70 0.22 (0.04–0.80)
GUD symptoms 1/25 4.00 3/44 6.82 0.59 (0.01–7.31)
No GUD 2/476 0.83 11/475 2.32 0.18 (0.02–0.83)
HSV-2 seroconverters
All 5/221 2.26 12/296.5 4.05 0.56 (0.19–1.57)
GUD symptoms 1/15.5 6.45 4/40.5 9.88 0.65 (0.01–6.60)
No GUD 4/205.5 1.95 8/256 3.13 0.62 (0.14–2.32)
HSV-2 negative
All 7/2,711.5 0.26 20/2,672 0.77 0.34 (0.15–0.81)
GUD symptoms 0/58.5 0 4/101.5 3.94 0.0 (0.0–2.63)
No GUD 7/2,653 0.26 16/2,570.5 0.64 0.42 (0.17–1.03)
95% CI based on an exact test when cell size was ,5 observations.
doi:10.1371/journal.pmed.1000187.t003
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Kalon index value of $1.1 for HSV-2 seropositivity as was used in
the South African study. Using these criteria, HIV incidence was
1.02/100 py (7/688.8 py) in the intervention arm and 2.04 (14/
686.5 py) in the control arm (IRR=0.50, 95% CI 0.20–1.23),
which is compatible with the protective effect of circumcision
among the HSV-2 positive men in the South African trial (0.37,
95% CI 0.09–1.55) [11].
HIV incidence was highest among HSV-2 seroconverters,
particularly if they reported GUD symptoms, and the risk of HIV
acquisition was lower but not statistically significant in circumcised
compared to uncircumcised men who acquired HSV-2
(IRR=0.56, 95% CI 0.19–1.57). The protective effects of
circumcision against incident HIV was most pronounced and
statistically significant in persistent HSV-2 negative men
(IRR=0.34, 95% CI 0.15–0.81). The numbers of HSV-2 negative
men with GUD were too small to estimate efficacy. The adjusted
incidence rate ratios (adjIRR) of HIV acquisition based on Poisson
multiple regression, were 0.58 (95% CI 0.39–0.87) for circumci-
sion, and 3.11 (95% CI 1.90–5.10) for GUD. Using persistent
HSV-2 negative men as the referent category, the adjIRRs of HIV
acquisition were 3.15 (95% CI 1.86–5.31) for enrollment HSV-2
positives, 4.81 (95% CI 2.62–8.84) for HSV-2 seroconverters, and
3.02 (95% CI 1.63–5.59) for men with indeterminate HSV-2
status. Previously married men were also at higher risk of HIV
(adjIRR 2.42, 95% CI 1.28–4.56).
Using mediation analysis, the estimated proportion of the HIV
incident effect of circumcision explained by the reduction in
symptomatic GUD among the circumcised men was 11.2%
(12[20.5451/20.6140], with 95% CI 5.0–38.0. There were
3,413 men who were HSV-2 negative at enrollment, and among
this subpopulation, the adjusted proportion of HIV incident
infections estimated to be mediated via HSV-2 seroconversion was
8.6% (95% CI 21.2 to 77.7). The confidence intervals are wide
due to small number of HSV-2 seroconversions, and this mediated
proportion estimate was not statistically significant.
Based on the data in Table 3, HIV incidence among
circumcised men reporting GUD symptoms was 2.89/100 py
compared with asymptomatic circumcised men (0.70/100 py),
and the IRR of HIV acquisition associated with GUD was 4.12.
The AR of HIV acquisition due to GUD in circumcised men was
10.7% (95% CI 21.8 to 221.6). Similarly, among uncircumcised
men, HIV incidence was 5.27/100 py in those with GUD
symptoms compared with 1.18/100 py in those without
symptoms (IRR=4.47). The AR of HIV acquisition attributable
to GUD in uncircumcised men was 18.1% (95% CI 6.8–27.9).
Therefore, ulceration contributed to a higher risk of HIV
acquisition in both uncircumcised participants and circumcised
participants, but confidence intervals were wide and the ARs of
GUD were not significantly different between the two arms (x
2,
p=0.34).
Similarly, we estimated the AR of HIV acquisition attributable
to HSV-2 seroconversion (compared to HSV-2 persistent
seronegative). In the intervention arm, the IRR of HIV acquisition
relative to persistent HSV-2 seronegative men was 8.69 (2.26/
0.26), and the estimate of AR was 36.9% (95% CI 21.7 to
260.8%). In the control arm, the comparable IRR was 5.26
(4.05/0.77), and the AR was 30.6% (95% CI 9.3–46.8%). This
suggests that HSV-2 seroconversion was associated with increased
risk of HIV acquisition in both the intervention and control arms,
but the ARs between the two arms were not significantly different
(p=0.63). Similar AR estimates for HSV-2 infections prevalent at
time of enrollment were: intervention arm 17.1%, 95% CI 24.3–
44.7, and control arm 29.8%, 95% CI 7.1–46.9, p=0.63.
Discussion
MC reduced symptomatic genital ulceration by 41%, and the
protection against GUD was similar irrespective of HSV-2 status
in this population (Table 2). We estimate that approximately
11.2% of the protection from HIV afforded by circumcision is
mediated by the reduction of symptomatic GUD due to
circumcision (Table 3). Thus, it is likely that the reduction in
symptomatic GUD made only a modest contribution to the overall
impact of circumcision on prevention of HIV infection.
The finding that circumcision reduced GUD in the men who
remained HSV-2 seronegative throughout the trial to approxi-
mately the same degree that it reduced GUD in HSV-2
seropositive men (Table 2) suggests that circumcision primarily
reduces the rate of nonherpetic ulceration. It is noteworthy that no
STI pathogens were detected in approximately 60% of ulcer swabs
tested by real-time PCR. Low rates of STI detection in ulcers have
also been reported among STD clinic patients with symptomatic
GUD [17], suggesting that a substantial proportion of ulcers are
not due to sexually transmitted organisms. It is possible that such
non-STI ulcers are due to trauma with secondary infections by
other pathogens. Such traumatic lesions may be more common in
uncircumcised men because the foreskin is retracted over the shaft
of the penis during intercourse and minor trauma, particularly to
the frenulum, is thought to be common [5]. Therefore, it is
possible that circumcision protects men from GUD largely by
preventing traumatic lesions.
We were surprised that circumcision did not significantly reduce
HIV acquisition among men who had prevalent HSV-2 at
enrollment, whereas the procedure was associated with lower HIV
risk in other groups, including men with HSV-2 indeterminate
status and (although not significantly) in seroconverters (Table 3).
It is possible that our failure to observe a protective effect of
circumcision in prevalent HSV-2 positive enrollees is due to
chance since this was a post hoc subgroup analysis that was not
specified in the protocol. Our finding is contrary to that reported
from the South African circumcision trial that observed similar
efficacy of circumcision for HIV prevention among HSV-2
seroprevalent and HSV-2 seronegative men [11,21]. However,
there were differences between the trials in the age of study
participants (18–24 y in South Africa versus 15–49 y in Rakai), the
definition of HSV-2 infection (Kalon index value of 1.1 in South
Africa, compared to 1.5 in Rakai based on our prior studies [15]),
and in HSV-2 prevalence (5.9% in the South African trial, 27.9%
in Rakai). Sensitivity analyses of the Rakai data using the same age
groups and HSV-2 diagnostic criteria as the South African trial
indicated comparable and nonstatistically significant estimates of
circumcision efficacy for HIV prevention (South Africa
IRR=0.37, 95% CI 0.09–1.55, Rakai IRR=0.50, 95% CI
0.20–1.23). These young men were likely to have more recently
acquired HSV-2, and thus potentially have active herpetic
infection. Therefore, one potential explanation for the divergence
of findings between the Ugandan and South African studies may
be attenuated efficacy of MC for HIV prevention in older men
with more chronic herpes infections, due to recruitment of CD4+
T cells and immature dendritic cells into areas of HSV-2
replication even months after resolution of lesions [22,23]. This
persistence of HIV receptor cells might explain why trials of HSV-
2 suppressive therapy did not show efficacy for HIV prevention
[24,25], and reinforces the need for circumcised men to maintain
safe sex practices (e.g., condom use or partner reduction) to avoid
infection with HIV or STIs.
There are limitations to this study—a secondary analysis of two
randomized trials that had not been prespecified in the trial
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observation in some subgroups, resulting in imprecise estimates.
To increase sample size, we pooled data from HIV-negative men
in two parallel trials, and although trial-specific findings were
similar, sample size constraints precluded many trial-specific
subgroup analyses (unpublished data). Self-reported symptomatic
GUD is subject to misclassification because respondents may fail
to recognize an ulcer or fail to recall it at time of interview. Also,
although men were asked about GUD symptoms in the preceding
interval, they were not asked about the duration of symptoms or
multiple episodes of ulceration, so severe recurrent ulcers are likely
to be underestimated. It is noteworthy that the efficacy of
circumcision for prevention of clinically observed GUD at time
of a study visit (PRR=0.44, 95% CI 0.32–0.61), was greater than
the efficacy estimated from the period prevalence of self-reported
symptoms (PRR=0.59, 95% CI 0.50–0.69), suggesting that the
latter may have been affected by misclassification because of
misreporting of symptoms.
In summary, we found that genital ulceration played only a
modest role in protection from HIV due to MC, and that the
reduction in self-reported GUD was observed in HSV-2
seronegative men, suggesting that the ulcers prevented by
circumcision are likely to be nonherpetic in origin. Thus, the
evidence suggests that most of the reduction in HIV risk afforded
by circumcision is attributable to removal of vulnerable foreskin
tissue containing HIV target cells.
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Background. Acquired immunodeficiency syndrome (AIDS)
has killed more than 25 million people since 1981, and more
than 30 million people (22 million in sub-Saharan Africa
alone) are now infected with the human immunodeficiency
virus (HIV), which causes AIDS. There is no cure for HIV/AIDS.
Consequently, prevention of HIV transmission is extremely
important. Because HIV is most often spread through
unprotected sex with an infected partner, individuals can
reduce their risk of becoming infected with HIV by
abstaining from sex, by having one or a few partners, and
by always using a male or female condom. In addition, three
large trials in sub-Saharan Africa (including one in Rakai,
Uganda) recently reported that male circumcision—the
removal of the foreskin, a loose fold of skin that covers the
head of the penis—can halve HIV transmission rates in men.
Thus, as part of its HIV prevention strategy, the World Health
Organization now recommends that male circumcision
programs be scaled up in countries where there is a
generalized HIV epidemic and where few men are
circumcised.
Why Was This Study Done? It is still not clear why male
circumcision reduces HIV acquisition in men. Certainly, the
foreskin contains many cells that HIV can infect and the
foreskin’s delicate lining is thought to be particularly
vulnerable to HIV infection partly because intercourse can
cause small tears in it through which HIV can enter the body.
But male circumcision also reduces genital ulcer disease—
sores on the penis and other genital organs caused by
infection with several sexually transmitted organisms
including the herpes simplex virus type 2 (HSV-2). Genital
ulcer disease, particularly when caused by HSV-2, is thought
to increase a person’s risk of acquiring HIV, so could male
circumcision reduce HIV transmission rates because of its
beneficial effects on genital ulcer disease rather than
through its removal of foreskin tissue with its rich source
of HIV target cells? In this study, the researchers investigate
this question by re-analyzing data collected in two Ugandan
trials of male circumcision for HIV prevention.
What Did the Researchers Do and Find? In the Ugandan
trials, the researchers randomly assigned about 5,500 HIV-
uninfected men to immediate circumcision or to
circumcision 24 months later. At enrollment, they asked
the men whether they had any symptoms of genital ulcer
disease (for example, a painful penile sore or genital itching),
examined the men’s genital areas, and took blood samples
to test for HSV-2 infection. The researchers repeated these
examinations and tests at 6 months, 12 months, and 24
months and tested the study participants for HIV infection.
The researchers’ statistical analysis of these data shows that
circumcision approximately halved symptomatic genital
ulcer disease in the study participants irrespective of their
HSV-2 infection status. Circumcision reduced the risk of HIV
acquisition in men without HSV-2 infection by two-thirds but
did not affect HIV acquisition among men infected with HSV-
2 at enrollment. Among the men who became infected with
HSV-2 during the study, circumcision reduced the risk of HIV
acquisition but this reduction in risk was not statistically
significant. That is, it could have happened by chance.
Finally, the researchers calculated that 11.2% of the observed
reduction in HIV acquisition associated with circumcision
was mediated by reductions in symptomatic genital ulcer
disease and 8.6% was mediated by reductions in HSV-2
infections.
What Do These Findings Mean? The findings of this
study are limited by the small number of people in some of
the subgroups analyzed and by genital ulcer disease being
self-reported. Furthermore, the validity of some of the
findings may be compromised because the analysis
described here was not specified in the original trial
protocol. Nevertheless, these findings suggest that the
reduction of genital ulceration following circumcision plays
only a minor part in the ability of male circumcision to
reduce HIV acquisition in men. They also suggest that
circumcision reduces genital ulcer disease primarily by
reducing the rate of nonherpetic ulceration, including sores
caused by mild trauma during intercourse. Thus, the
researchers conclude, most of the reduction in HIV
acquisition provided by male circumcision may be
attributable to the removal of vulnerable foreskin tissue
containing HIV target cells.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000187.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Uganda, and on circumcision and
HIV (in English and Spanish)
N More information about male circumcision is available
from the Clearinghouse on Male Circumcision
N Information on the Rakai HIV prevention trial is available
N The MedlinePlus Encyclopedia has a page on male genital
sores (in English and Spanish)
N The US National Institute of Allergy and Infectious Diseases
provides information about genital herpes
N The US Centers for Disease Control and Prevention also
provides information on genital herpes (in English and
Spanish)
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